ABBV P/E Ratio Analysis

AbbVie’s price-to-earnings (P/E) ratio of 103.8x means investors are paying $103.80 for every $1 of the company’s annual earnings, a very high multiple that typically signals expectations of strong future growth.

This is far above the healthcare sector median of 28.3x and places AbbVie in the 100th percentile among its peers, meaning virtually all other sector stocks have a lower P/E. The metric has been perfectly stable over the last eight quarters, with year-over-year and quarter-over-quarter changes both at +0.0%. The combination of an extremely elevated P/E and no movement in the ratio suggests the market has fully priced in anticipated growth without any recent re-rating, which leaves little margin for error if earnings disappoint. This level of valuation implies above-average downside risk if growth slows, yet the stability offers no signal of a near-term catalyst for change. The neutral overall verdict is supported: the expensive P/E warns of potential overvaluation, but the flat trend shows no deterioration, balancing the outlook.

Frequently Asked Questions

Closest Sector Peers